SMALTIS is a company created by two young doctors in bacteriology, Sophie GUENARD and Cédric MULLER. Its team is composed of microbiology experts, who aim to support various public and private actors in their health product development projects, from research to clinical studies.
SMALTIS thus, offers tailor-made solutions with high added value, to fight against antibiotic resistance, to explore microbiota, and to optimize bioprocesses through bacterial strain engineering.
SMALTIS’ services and products allow, for example, to assess the risk of antimicrobial resistance of new antimicrobial candidates, to understand the interactions between a compound and the intestinal microbiota, or to build a modified bacterial strain to simplify a bioproduction process.
Catalogues of clinical or reference strains, genetically modified or not, well characterized, are also available, as well as analytical services.
In order to ensure a high level of quality for its customers, the laboratory is certified ISO 9001.
*Our watchwords are stringency, efficiency, responsiveness and flexibility, IN COMPLETE CONFIDENTIALITY.*
**Publications** - Guénard, S., Muller, C., Monlezun, L., Benas, P., Broutin, I., Jeannot, K., and Plesiat, P. (2013) Multiple mutations lead to MexXY/OprM-dependent aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa. Antimicrob Agents Chemother.* - Buyck, J. M., Guénard, S., Plesiat, P., Tulkens, P. M., and Van Bambeke, F. (2012). Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. *J Antimicrob Chemother* 67, 771-5. - Muller, C., Plesiat, P., and Jeannot, K. (2011). A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 55, 1211-21. - Vettoretti, L., Plesiat, P., Muller, C., El Garch, F., Phan, G., Attree, I., Ducruix, A., and Llanes, C. (2009). Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 53, 1987-97.
**Awards** - July 2013: Winner of the 15th national competition for assistance in the creation of innovative technology companies, organised by the Ministry of Higher Education and Research in partnership with Bpifrance funding. - 2012: Winner of the "Entrepreneuriales 2012" competition.
SMALTIS can identify and quantify the different bacterial species which may be present in a sample or on a surface.
Applications which can be considered:
Gene inactivation by homologous recombination (creation of knockout bacteria)
Through gene inactivation by a homologous recombination technique leading to the total deletion of the gene (near to the base) without leaving any additional DNA sequences (antibiotic resistance cassettes), SMALTIS can construct for you the deletion mutants (knockout) you need for Pseudomonas aeruginosa, P. fluorescens, Klebsiella pneumoniae or other bacteria. Thanks to this capability, you can obtain KO mutants derived from your own bacterial strains.
We can also complement chromosomally the various genetic targets in your bacterial strains.
Applications which can be considered:
Determination of resistance to different drugs
We can perform in vitro determination of the sensitivity of your bacterial strains to various drugs, such as antibiotics, antiseptics, dyes, etc.
SMALTIS can also identify the associated resistance mechanisms, as well as their genetic origin.
Panel of methods available:
SMALTIS has developed a partnership with a company specialized in the next generation sequencing technologies which allows us to perform whole bacterial genome sequencing.
We can perform chromosomal directed mutagenesis to modify directly one or more nucleotides of a chromosomal sequence.
As recommended by CLSI and CA-SFM.
"It was my pleasure working with SMALTIS, the report was well written and delivered on time, i highly recommend this lab."
SMALTIS has not received any endorsements.